Ventricular Tachycardia Case Summary

At this point, we do not know exactly what are the settings, we have previous requested pacemaker operative report from Regions. Unfortunately, from what he is telling today, his date of the birth was not correct as such dose report were not same. He noted that he thinks he came back from the hospital, he has not had similar complaint or concern or report of chest pain. It should be noted that hospital records, with a troponin that was negative, 12-lead EKG was similar to the one that was obtained here, essentially identifying sinus bradycardia with first-degree AV block, left ventricular hypertrophy with repolarization abnormality. QT was prolonged, similar EKG obtained at facility also identified pretty much the same abnormality pattern. Troponin was negative. Other workup included chest x-ray in the hospital were all unremarkable. Today he is not reporting any chest pain, no shortness of breath, no nausea or emesis. He has got healed ____ scar to the left chest from pacemaker implantation which is completely healed but slightly

A.O. is an 89-year-old woman with a long history of systolic heart failure secondary to a large left ventricular infarct when she was in her 70s. She had poor activity tolerance and required assistance with activities of daily living. Even minimal activity was associated with moderately severe dyspnea and exertional chest pain, which was relieved by rest. A.O. also exhibited marked pedal edema bilaterally. She is being treated with digitalis, furosemide (Lasix), KCl, and sublingual nitroglycerin.

Kay, Neal, and Gregory T. Bittner. "Should Implantable Cardioverter-defibrillators and Permanent Pacemakers in Patients with Terminal Illn

Mr. Howard, a 57-year-old man, had a 3-month history of progressive typical anginal chest pain. He reported that the symptoms first occurred with heavy exertion and involved what he described as“heaviness” in his chest. The symptoms were promptly relieved with rest. Over the past weeks, he had been experiencing increasingly frequent episodes of chest pain and diaphoresis. The episodes had become more prolonged, and he had experienced one episode of pain occurring at rest after a heavy meal. Mr. Howard was moderately obese and had a 20-year history of hypertension, which was being treated. Other risk factors in Mr. Howard’s history include hypercholesterolemia (350 mg/dL), which he was attempting to treat with dietary modifications, and a 30-year two-pack-a-day smoking history which continued up to the present time. Mr. Howard previously had surgery for a bilateral inguinal hernia repair, cholecystectomy, and arthroscopic surgery on his left knew. He also gave a history of problems with gastric reflux and was currently taking cimetidine (Tagamet).

Among the indications for Ventricular Assist Device the presence of decompensated or life-threatening end-stage cardiac disease, for patients with severe circulatory compromise, and when hypo-perfusion, cardiogenic shock, failure to wean off cardiopulmonary bypass after surgery. Also, as destination therapy for patients that are not good candidates for a heart transplant; or inability to wean off from cardiopulmonary bypass after surgery.

RESPONSE: Yes. There are no alternative treatments to the use of the LIFE Vest during this period of time. The only other option is pure observation, which will clearly not treat any life threatening arrhythmias. There is no trial with drug data to say that any pharmacologic agent is sufficient during this period.

43 percent of alarm conditions indicated non-critical, and “generally non-actionable,” events; 38 percent of alarm conditions indicated premature ventricular complexes (PVCs), which, since a landmark 1988 Cardiac Arrhythmic Suppression Trial (CAST) study, are no longer treated; and 3.6 percent of alarm

Continuous cardiac monitoring remains the gold standard for arrhythmia detection, we would keep Mrs. Lee on continuous monitoring to provide complete uninterrupted arrhythmia monitoring of her rate and rhythm (Andrade et al,2015).

This past year has been really hard for me, especially how I feel physically and emotionally. In May, I started getting really sick, I was laying down a lot, I felt very weak, and loud noises or anything stressful upset me. My heart was having problems. I first started noticing this at the end of May. I went to the doctor, and they told me that I had anxiety, but I really don’t feel anxious at all. When seeing papers, and records that nurses and doctors had recorded about me, it stated that what I had was called Sinus Tachycardia. What this means is that my heart goes fast, and never goes slow. This has been really hard for me, and i’ve gotten so use to the fact, that my heart goes fast, that if it were to go slow, that would feel weird to

Heart disease is a very common medical issue, and scientists and doctors have been looking for decades to improve the lives of those who suffer from these conditions. The heart begins to fail once it cannot supply enough blood to the body. In most cases, the only solution was a total heart transplant. These transplants come from donors, and thousands of people are on waiting lists for these hearts. For many years, doctors could use various heart implants that would assist the heart in functioning. These implants acted as a bridge until the patient could receive a full transplant from a donor. But, implants such as pacemakers always have the associated risk of infections. Procedural infections and respiratory infections are commonplace with

An dysrhythmia of the heart is an irregular heartbeat rhythm. Ventricular tachycardia is an dysrhythmia in which the lower chambers of the heart, the ventricles, beat unusually fast.

A week later he had similar complaints and positive troponin with diffuse ST segment depressions on ECG. Repeat angiogram revealed nonobstructive coronaries. He then had 3 more admissions for HF within a month. His EF declined from 45% to 20% and he was in low output HF requiring an intra-aortic balloon pump (IABP) and inotropes. Right heart catheterization revealed elevated filling pressures. Endomyocardial biopsy showed extensive AL amyloid deposition (lambda) with replacement fibrosis. Serum kappa and lambda light chains were 2.5 and 38.4 mg/dl respectively, with a ratio of 0.0643 (normal 0.26-1.65). After a bone marrow biopsy showed a 3% clonal lambda population, he was started on cyclophosphamide, bortezomib and dexamethasone. A left ventricular assist device (LVAD) was placed to allow further chemotherapy and the possibility of cardiac recovery. The patient remains alive 6 months after LVAD implantation on chemotherapy. Discussion: Cardiac amyloidosis, especially TTR, usually presents gradually with restrictive HF. AL amyloid may have a more rapid symptom onset and

Methods to identify appropriate treatments for the various stages of ventricular fibrillation (VF) involve differentiating groups of subjects who will respond to defibrillation with return of spontaneous circulation (ROSC) and those who require other therapies (e.g., CPR, drugs) prior to defibrillation. The use of quantitative waveform measures (QWM) which measure the frequency and fractal dimension of the VF electrocardiogram have shown success in predicting response to defibrillatory shock in animal models. Patients in cardiac arrest are often taking medications affecting adrenergic activity such as the beta blocker metoprolol and the combined alpha and beta blocker, labetalol. How this exposure might alter the QWM and ROSC

The concept of non-invasive cardiac pacing has been present for about 200 years. In 1791 Galvani reported that an electrical current applied across the heart of a dead frog resulted in myocardial contraction [1]. However, non-invasive pacing was not made practical until Dr. Paul Zoll's work in the early 1950s. In 1952 Zoll reported the successful delivery of current from a generator through subcutaneous needle electrodes, which resulted in fixed rate pacing of two patients with ventricular standstill.3 He later reported the development and successful use of the first true noninvasive pacemaker and monitor. This device used a pair of 3-centimeter diameter metal electrodes secured to the chest wall with a leather belt and delivered 2-20 millisecond,

Background: Batten Disease is a rare and fatal autosomal recessive neurodegenerative disorder, regarded as the juvenile form of neuronal ceroid lipofuscinoses (NCL). It is most commonly associated with mutations in the CLN3 gene and involves lipofuscins accumulation in the neuronal tissues. We present a case of first degree arterioventricluar block in a patient with batten disease, treated with permanent pacemaker implantation